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mitochondria-mediated apoptosis. GANT61 inhibited the 
expression of GLI and Bcl-2 at both the mRNA and protein 
levels and might affect the expression of Bax, caspase-3 
and caspase-9 to promote cell intrinsic apoptosis. Further-
more, GANT61 could enhance cisplatin-induced apoptosis 
to decrease the IC50 value of cisplatin. Finally, data sug-
gest that GANT61 could enhance cisplatin-induced apopto-
sis through promoting the expression of Bax, caspase-3 and 
caspase-9 protein levels.
Conclusion Our data suggest that the SHH signalling path-
way plays an important role in MB. GLI is an oncogenic 
transcription factor in the SHH pathway, and targeting GLI 
with GANT61 results in favourable antitumour activity and 
targeted therapy.
Keywords Medulloblastoma · SHH signalling pathway · 
GANT61 · GLI · Bcl-2 · Mitochondria-mediated apoptosis
Abbreviations
SHH  Sonic hedgehog
MB  Medulloblastoma
GLI  Glioma-associated oncogene homologue
Bcl-2  B cell leukaemia lymphoma-2
Caspase-3  Cysteinyl aspartate-specific proteinase-3
Caspase-9  Cysteinyl aspartate-specific proteinase-9
GANT61  GLI inhibitor
mRNA  Messenger ribonucleic acid
IC50  Half-maximal inhibitory concentration
DMSO  Dimethyl sulphoxide
Introduction
Medulloblastoma (MB) is one of the most aggressive brain 
tumours in the paediatric patient and is characterized by 
Abstract 
Purpose The sonic hedgehog (SHH) signalling pathway 
plays the important role in medulloblastoma (MB). Altered 
GLI expression plays a key role in these processes, and the 
inhibition of GLI may be a good cancer-targeted therapy. 
This study aimed to investigate whether GANT61, a GLI 
inhibitor, may inhibit the SHH signalling pathway promot-
ing cell mitochondria-mediated apoptosis and enhance cis-
platin apoptosis antineoplastic therapy.
Methods In our study, we determined the effect of 
GANT61-mediated inhibition of GLI in Daoy MB cells. 
Cells were treated with different concentrations of GANT61 
alone or in combination with cisplatin. Cell proliferation was 
assessed with CCK-8 assays, and cell invasion and migration 
were performed using 8-µm transwell inserts. Cell apoptosis 
was assessed with flow cytometric analysis and rhodamine 
123. qPCR was used to complete RNA experiments. Protein 
expression was assessed with Western blotting.
Results The GANT61 significantly inhibited cell prolifera-
tion. GANT61 decreased the cell migration and invasion, 
impairing these crucial steps in tumour progression. Cell 
apoptosis was significantly increased in Daoy cells. Rho-
damine 123 assay showed that GANT61 could decrease 
the mitochondrial membrane potential promoting cell 
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high mortality and poor prognosis (Gerber et al. 2014). 
Through current multimodality therapy, many patients 
have good prognosis; however, many of them suffer from 
considerable disability and morbidity (Moxon-Emre et al. 
2014; Rutkowski et al. 2010). Therefore, it is necessary to 
increase understanding of the pathogenesis underlying MB 
to develop satisfied targeted therapy.
The sonic hedgehog (SHH) signalling pathway has an 
important role in embryonic development and in the regula-
tion of a variety of cellular functions (Scales and de Sauvage 
2009). Aberrant activation of SHH signalling has been impli-
cated in several human cancers, including MB, basal cell car-
cinoma and pancreatic cancer (Ozgur et al. 2015; Von Hoff 
et al. 2009). The zinc finger transcription factor GLI, includ-
ing GLI1 and GLI2, is considered a mediator of the SHH 
pathway in MB. GLI is possibly an oncogenic gene and is 
also involved in cell proliferation and apoptosis. To shed 
light on the role of GLI in MB, we screened for genes prefer-
entially regulated by GLI in MB cells.
GLI has also been implicated in the mitochondrial apop-
tosis signalling pathways; for example, the apoptosis genes 
caspase-3 and caspase-9 were identified as direct transcrip-
tional targets of GLI (Graab et al. 2015). The role of GLI 
in the induction of apoptosis has also been investigated in 
the several human cancer cells expressing Bcl-2 (Wang 
et al. 2010). We show here that expression of the typical 
oncogene Bcl-2 and Bax is predominantly activated by 
GLI. Bcl-2 plays an important role in the intrinsic apoptotic 
pathway, acting as the protection of the mitochondria by 
inhibiting the activation of Bax, caspase-3 and caspase-9 
(Marsden et al. 2002, 2004). Caspases are crucial media-
tors of programmed cell death. Among them, caspase-3 is 
an important activated death protease and is essential for 
certain processes associated with apoptosis. Many research 
report that, in a wide variety of tumour cells, GANT61-
induced apoptosis is also dependent on the expression of 
caspases (Fu et al. 2013; Matsumoto et al. 2014a; Mazum-
dar et al. 2011a, b; Pan et al. 2012a; Wickstrom et al. 
2013). Therefore, the overexpression of Bax, caspase-3 and 
caspase-9 in conjunction with the inhibition of GLI activity 
might suppress Bcl-2 activation, accelerating apoptosis.
Many research reports that, in several tumour cell types, 
the forced overexpression of Bcl-2 has been considered 
resistance to chemotherapeutic agents (Pilco-Ferreto and 
Calaf 2016; Wang and Teng 2016). Chemotherapeutic 
drugs have important roles in anticancer therapy, because 
they can induce DNA double-strand breaks, accelerating to 
tumour cells apoptosis. But tumour cells often generated 
resistant to chemotherapeutic drugs, it is very important 
to determine the path mechanisms of the drug resistance. 
Many reports have showed that GLI protein level decreases 
in a dose-dependent manner in response to GANT61 treat-
ment (Kramann et al. 2015; Moshai et al. 2014; Srivastava 
et al. 2014). GLI is considered to be a master regulator of 
the SHH pathway by regulating the genes expression that 
are crucial for cell apoptosis. GLI is overexpression in sev-
eral human cancers, indicating that targeting GLI could 
be an attractive therapeutic strategy against human can-
cers (Desch et al. 2010; Pan et al. 2012b; Stecca and Ruiz 
2010). GANT61 is one of the agents identified as having 
inhibitory effects on the SHH pathway (Desch et al. 2010; 
Mazumdar et al. 2011a, b; Mechlin et al. 2010). It acts by 
selectively binding to GLI and has also been found to sup-
press tumour proliferation (Mechlin et al. 2010). In our 
study, GANT61 had in vitro activity against tumour prolif-
eration and induced cell apoptosis. Furthermore, we found 
that GANT61 can inhibit the expression of GLI mRNA and 
protein. Suppressing the expression of GLI1 inhibited the 
overexpression of Bcl-2 and the proliferation of tumour 
cells while simultaneously promoting cell apoptosis.
In summary, these researches show that GANT61 is an 
effective treatment for MB. In our study, we determined 
the antitumour effects and the apoptosis mechanisms of 
GANT61. We further determined the ability of GANT61 to 
sensitize Daoy cells to cisplatin, which is commonly used 
to treat MB. Thus, it may be an attractive therapeutic strat-
egy to block the expression of GLI in MB.
Materials and methods
Reagents and antibodies
GANT61 purchased from Sigma-Aldrich (St. Louis, MO, 
USA) was dissolved in DMSO and stored at −20 °C. Cis-
platin was obtained from Sigma-Aldrich and was dissolved 
at a stock concentration of 2 mmol/L. Rhodamine 123 was 
purchased from Sigma-Aldrich. Foetal bovine serum (FBS) 
and 0.25 % trypsin/EDTA were bought from Gibco Life 
Technologies (Carlsbad, CA, USA). A FITC-annexin V 
kit was purchased from Abcam (Cambridge, MA, USA). 
The CCK-8 cell count kit for cell proliferation analysis 
was purchased from Tongren Chemical Research Institute 
(Kyushu, Japan). The reverse transcription kit was pur-
chased from Takara (Shiga, Japan). SYBR Green I was pur-
chased from Noble Ryder (Beijing, China). Antibodies for 
GLI1 (ab49314), GLI2 (ab26056), Bax (ab10813), BCL-2 
(ab59348), caspase-3 (ab32351) and caspase-9 (ab25758) 
were purchased from Abcam (Cambridge, MA, USA). The 
β-actin antibody (AP0060) was purchased from Bioworld 
(Louis Park, MN, USA).
Cell culture
The Daoy MB cell line was purchased from ATCC. 
Daoy cells were maintained in RPMI 1640 medium 
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supplemented with 10 % foetal bovine serum at 37 °C with 
5 % CO2. Before each experiment, trypan blue staining was 
used to define the cell viability. The cell viability was deter-
mined to be over 98 %.
Cell proliferation analysis
The cell proliferation assay was assessed with CCK-8. 
Daoy cells in the exponential growth phase were pipetted 
into single cells after trypsin digestion. Eight thousand cells 
were seeded in each well of a 96-well plate. RPMI 1640 
medium containing 10 % FBS was used to culture the cells 
for 24 h before being replaced by serum-free medium. The 
cells were starved for 6 h and then incubated in RPMI 1640 
medium containing 1 % FBS. Different concentrations of 
GANT61 (10, 20 and 40 μM) were added with or with-
out cisplatin, with normally growing cells as the negative 
control and cell-free wells as the blank control. Each group 
was set with six replicates. The cells were continually cul-
tured in the incubator for another 24 h before the culture 
medium was removed. One hundred microlitres of fresh 
RPMI 1640 medium and 10 μL of CCK-8 solution were 
then added into each well. Cytotoxicity was also assessed 
with CCK-8 assays. Cells were cultured in the different 
concentrations of cisplatin (0–70 µM/L) with or without 
GANT61 (10 µM/L) for 24 h. The cells were placed in the 
incubator to avoid light. Absorbance at 450 nm was meas-
ured at 30 min, 1, 2 and 4 h. The proliferation inhibition 
rate was calculated as follows: (A450 of negative control 
group−A450 of GANT61-treated group)/A450 of negative 
control group × 100 %.
Cell invasion and migration assay
Cells were treated with the different concentrations of 
GANT61 (10, 20 and 40 μM) for 24 h, and equal numbers 
of cells were treated with serum-free medium. Each group 
was assessed with migration assays or invasion assays. 
The mean number of cells was calculated in five randomly 
selected high-power fields.
Flow cytometry
Cells were collected into 10-mL centrifuge tubes and cen-
trifuged for 5 min at 500–1000 rpm. The culture medium 
was discarded. Cells were then washed once with the incu-
bation buffer and centrifuged for 5 min at 500–1000 rpm. 
PI was dissolved at a final concentration of 1 μg/mL in 
the incubation buffer along with FITC-annexin V to gen-
erate the marking buffer. Resuspended cells were labelled 
with 100 μL of solution buffer in the dark for 10–15 min 
at room temperature. Cells were then precipitated by cen-
trifugation at 500–1000 rpm for 5 min and washed with 
incubation buffer. The sample was incubated at 4 °C for 
20 min in the dark without shaking. For the flow cytom-
etry analysis, the excitation and detection wavelengths for 
the FITC channel were 488 and 515 nm, respectively, while 
another filter with a wavelength greater than 560 nm was 
used for PI.
Rhodamine 123
Daoy cells were seeded on glass coverslips and treated with 
different concentrations of GANT61. Twenty-four hours 
after incubation, the cells were fixed with rhodamine 123 
for 30 min. Then, the cells were washed with PBS. The 
cells were mounted and observed under a fluorescence 
microscope.
PCR array analysis
Cells were treated with RPMI 1640 medium plus 10 % 
FBS. The medium was changed to RPMI 1640 medium 
plus 10 % FBS without (control) or with GANT61 after 
24 h. Total RNA was extracted from the cells with TRIzol. 
Then it was treated with PrimeScript™ RT Master Mix 
(Takara, Japan) for removal of contaminating DNA. Then, 
samples were tested with a PCR array (Takara, Japan). 
Data were analysed with the ΔΔCt method.
Western blotting
Cells were synchronized in RPMI 1640 medium plus 10 % 
FBS and exposed to different concentrations of GANT61 
for 24 h. We measured the protein profile of the cells with 
Western blot analysis. Cells were collected and washed 
with PBS three times. Then, the cells were lysed in fresh 
RIPA protein lysis buffer containing 1 % PMSF on ice. The 
total protein concentration was determined with the BCA 
method. After separation by SDS–PAGE electrophoresis, 
the samples were transferred to PVDF membrane. Protein 
blots were visualized with Ponceau S staining. The mem-
brane was then blocked for 2 h at room temperature with 
gentle shaking. GLI1, GLI2, Bax, BCL-2, caspase-3 and 
caspase-9 antibodies were added for an overnight incuba-
tion at 4 °C. The membrane was then incubated with the 
secondary antibody (1:10,000) at room temperature for 1 h 
and washed three times with TBST buffer. ECL chemilu-
minescence reagent and Bio-Rad exposure apparatus were 
used for exposure.
Statistical analysis
The statistical software SPSS 19.0 was used for statistical 
analysis. Data were statistically analysed using analysis of 
variance. IC50 for each drug was calculated from linear 
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transformation of dose–response curves. All experimental 
data are expressed as the mean ± standard deviation (SD). 
*P < 0.05 indicates a statistically significant difference.
Results
GANT61 inhibits the cell migration and invasion
GLI plays an important role in tumour metastasis. Because 
tumour cell migration and invasion are important steps in 
tumour metastasis, we determined the effects of GANT61 
on cell migration and invasion. As shown in Fig. 1a, b, the 
migration and invasion capacity was assessed with tran-
swell assays. Figure 1c, d shows that GANT61 inhibited 
the cell migration and invasion capacity in a dose-depend-
ent manner (P < 0.05).
GANT61 inhibits proliferation and promotes apoptosis 
of Daoy cells
To elucidate whether cell proliferation was decreased in 
the presence of GANT61, Daoy cells were treated with 
different concentrations of GANT61 for 24 h. Cell prolif-
eration was determined with a CCK-8 assay. As shown in 
Fig. 2a, GANT61 significantly inhibited the proliferation 
of Daoy cells. This inhibition was dose-dependent and 
differed significantly from the control group (P < 0.05). 
To see whether GANT61 treatment could induce apopto-
sis, normally growing Daoy cells were treated with differ-
ent concentrations of GANT61. After 24 h, the cells were 
subjected to flow cytometry. As shown in Fig. 2b, c, the 
number of cells undergoing apoptosis increased signifi-
cantly compared with the untreated group (P < 0.05). These 
results verified the hypothesis that GANT61 induces apop-
tosis in Daoy cells.
GANT61‑induced alterations in the mitochondrial 
membrane potential promote apoptosis in Daoy cells
To see whether GANT61 treatment could induce apopto-
sis through the mitochondrial pathway, normally growing 
Daoy cells were treated with different concentrations of 
GANT61. After 24 h, the cells were stained with rhoda-
mine 123. As shown in Fig. 3a, b, the mitochondrial mem-
brane potential decreased significantly compared with the 
Fig. 1  GANT61 inhibits the cell migration and invasion. a, b The 
migration and invasion capacity was assessed with transwell assays. 
c, d GANT61 inhibited the cell migration and invasion capacity in 
a dose-dependent manner (P < 0.05). The cells were subjected to 
inverted microscopic observation (×100)
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Fig. 2  GANT61 inhibits proliferation and promotes cell apoptosis of 
Daoy cells. The effects of GANT61 treatment on proliferation were 
determined with CCK-8 assay. GANT61 inhibited the cell prolifera-
tion in Daoy cells (a). The inhibition was dose-dependent compared 
with the control group (P < 0.05). The effects of GANT61 treat-
ment on cell apoptosis were determined with FITC-annexin V flow 
cytometry analysis. b, c The number of cells undergoing apoptosis 
increased significantly compared with the untreated group (P < 0.05)
Fig. 3  GANT61 inhibited mitochondria membrane potential pro-
motes cell apoptosis of Daoy cells. The cells treated with differ-
ent concentrations of GANT61 were subjected for rhodamine 123 
after 24 h. a, b Mitochondria membrane potential decreased signifi-
cantly compared with the untreated group (P < 0.05). The cells were 
mounted and observed under fluorescence microscope (×200)
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untreated group (P < 0.05). These results verified the pre-
diction that GANT61 induces apoptosis through the mito-
chondrial pathway.
GANT61 inhibits the expression of GLI and Bcl‑2 
at both the mRNA and protein levels
To explore the mechanism linking cell apoptosis and GLI, 
total RNA was extracted from cells, reverse transcribed into 
cDNA and subjected to qPCR. GLI (GLI1 and GLI2) is an 
important transcription factor in the SHH signalling path-
way, regulating the transcription of multiple downstream 
target genes. One of these targets is Bcl-2. Bcl-2 is an 
oncogene that controls cell apoptosis. As shown in Fig. 4a, 
GANT61 significantly inhibited the expression of GLI1 
and GLI2 (P < 0.05). Along with the decreased expression 
of the GLI1 and GLI2 genes, Bcl-2 mRNA appeared to 
be simultaneously down-regulated (P < 0.05). The effects 
of GANT61 treatment on the SHH signalling pathway at 
the protein level were assayed with Western blotting. Fig-
ure 4b, c shows that GANT61 can decrease the level of 
GLI1 and GLI2. With the decreased expression of the GLI 
protein, the Bcl-2 protein appeared to be down-regulated 
(P < 0.05). The inhibition of GLI and Bcl-2 by GANT61 
occurred in a dose-dependent manner (P < 0.05). These 
results are basically consistent with the qPCR data show-
ing that GANT61 can significantly inhibit GLI1, GLI2 and 
Bcl-2 expression at the mRNA level.
GANT61 affects the expression of Bax, caspase‑3 
and caspase‑9, promoting cell intrinsic apoptosis
To further study the relationship between mitochondria and 
genes involved in cell intrinsic apoptosis, such as Bax, cas-
pase-3 and caspase-9, the levels of these transcripts were 
detected through qPCR analysis. As shown in Fig. 5a, 
along with decrease in the expression of the GLI1 gene, 
GANT61 appears to simultaneously up-regulate Bax, cas-
pase-3 and caspase-9 mRNA levels (P < 0.05). Figure 5b, 
c shows that, along with decrease in the expression of the 
GLI1, GLI2 and Bcl-2 proteins, GANT61 appears to simul-
taneously up-regulate Bax, caspase-3 and caspase-9 protein 
levels. These results show that GANT61 might have effects 
on mitochondrial-mediated cell intrinsic apoptosis.
Fig. 4  GANT61 inhibits the expression of GLI1, GLI2 and Bcl-
2. a GANT61 significantly inhibited the expression of GLI1 and 
GLI2 (P < 0.05). Along with the decreased expression of the GLI1 
and GLI2 genes, Bcl-2 mRNA appeared to be simultaneously down-
regulated (P < 0.05). The effects of GANT61 treatment on the SHH 
signalling pathway at the protein level were assayed with Western 
blotting. b, c GANT61 can decrease the level of GLI1 and GLI2. 
With the decreased expression of the GLI protein, the Bcl-2 protein 
appeared to be down-regulated (P < 0.05). The inhibition of GLI and 
Bcl-2 by GANT61 occurred in a dose-dependent manner (P < 0.05)
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GANT61 enhances cisplatin‑induced, caspase‑mediated 
apoptosis in Daoy cells
The overexpression of GLI may be closely related to 
chemotherapy resistance, and the suppression of GLI can 
increase the sensitivity to chemotherapeutical drugs (Zah-
reddine et al. 2014). We further determined whether com-
bining GANT61 with cisplatin would enhance the effect. 
Figure 6a show that combined treatment reduced the IC50 
value of cisplatin from 34.47 to 30.02 µmol/L. To charac-
terize GANT61-mediated enhancement of apoptosis, Daoy 
cells were exposed to different concentrations of GANT61 
(10 µm/L) with or without cisplatin (30 µm/L) for 24 h. To 
investigate the pathomechanism leading to cell apoptosis, 
we investigated the combined effect of GANT61 and cis-
platin on the expression of Bcl-2, Bax, caspase-3 and cas-
pase-9. As shown in Fig. 6b, the down-regulation in Bcl-2 
expression was significantly greater in the groups treated 
with both GANT61 (10 µm/L) and cisplatin (30 µm/L) 
than those in the single treatment group. However, com-
bination treatment emerged greater increase in Bax, cas-
pase-3 and caspase-9 protein expression than either drug 
alone group.
Discussion
Medulloblastomas are the most common malignant brain 
tumours in children and are associated with significant 
morbidity and mortality. Several reports have shown that 
the SHH signalling system is highly activated in medul-
loblastoma (Justilien and Fields 2015; Matsumoto et al. 
2014b). The zinc finger transcription factor GLI, including 
GLI1 and GLI2, is considered to be mediator of the SHH 
pathway in MB (Matsumoto et al. 2014b). To shed light on 
the role of GLI in MB, we screened for genes preferentially 
regulated by GLI. We showed here that the expression of 
the typical oncogene Bcl-2 is predominantly activated by 
GLI. To further clarify the mechanism of apoptosis, we 
investigated the relationship between Bax, caspase-3, cas-
pase-9 and GLI.
GANT61 is one of the agents capable of inhibiting 
the SHH pathway. It acts by selectively binding to GLI 
and has also been found to suppress tumour prolifera-
tion. In our study, GANT61 inhibited tumour prolifera-
tion and induced cell apoptosis in vitro. Furthermore, we 
found that GANT61 can inhibit GLI, including GLI1 and 
GLI2, mRNA and protein expression. Bcl-2 is one of the 
Fig. 5  GANT61 maybe affects expression of Bax, caspase-3 and 
caspase-9 promoted cell intrinsic apoptosis. a Along with decrease in 
the expression of the GLI gene, GANT61 appears to simultaneously 
up-regulate Bax, caspase-3 and caspase-9 mRNA levels (P < 0.05). 
b, c Along with the decreased expression of GLI1, GLI2 and Bcl-2 
protein, Bax, caspase-3 and caspase-9 protein appeared to be up-regu-
lated synchronously
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oncogenes controlling apoptosis. We investigated whether 
GLI1 has a relationship with the typical oncogene Bcl-2 
in cell apoptosis. Bcl-2 is a key protein in apoptosis and is 
highly expressed in multiple types of tumours (Janumyan 
et al. 2003). We found that the expression of GLI mRNA 
was significantly associated with Bcl-2 expression, as was 
protein levels. Suppressing the expression of GLI could 
inhibit the overexpression of Bcl-2 and the proliferation 
of tumour cells, simultaneously promoting apoptosis. Our 
findings suggest that Bcl-2 down-regulation may account 
for the increased cell death that occurs after the suppression 
of GLI in combination with DNA damage. Thus, it may be 
an attractive therapeutic strategy to block the expression of 
GLI in MB.
Bcl-2 plays an important role in the mitochondrial path-
way of apoptosis (Wang et al. 2015). Bcl-2 can activate the 
transcription of a series of genes, such as Bax, caspase-3 
and caspase-9 (Autret and Martin 2009). Caspases are cru-
cial mediators of programmed cell death (Wen et al. 2012). 
Among them, caspase-3 is a frequently activated death 
protease and is essential for certain processes associated 
with apoptosis (Porter and Janicke 1999). Some pathways 
leading to caspase-3 activation have been determined to 
depend on caspase-9 function (Brentnall et al. 2013). Our 
results show that GANT61 can inhibit proliferation and 
promote cell apoptosis. Then, rhodamine 123 and flow 
cytometry showed that GANT61 might promote apoptosis 
by inhibiting the establishment of mitochondrial membrane 
potential. The qPCR and WB results show that GANT61 
inhibits the expression of Bcl-2; however, Bax, caspase-3 
and caspase-9 appeared to be simultaneously up-regulated. 
These results show that GANT61 might inhibit mitochon-
dria membrane potential to promote cell apoptosis. Thus, 
blocking the expression of GLI might be an attractive ther-
apeutic strategy for MB.
The overexpression of Bcl-2 is closely related to chemo-
therapy drug resistance, and the suppression of Bcl-2 has 
been shown to increase the sensitivity of tumour cells to 
chemotherapeutical drugs (Ogura et al. 2016). GANT61 
can decrease Bcl-2 transcript levels through the down-
regulation of GLI. We further assessed whether combining 
GANT61 with standard chemotherapeutic medicine would 
enhance this effect. The results showed that combined 
treatment reduced the IC50 value of cisplatin from 34.47 
to 30.02 µmol/L. To investigate the role of the SHH signal-
ling pathway in cisplatin resistance, we assessed the protein 
profile with Western blotting. GANT61 might activate Bax, 
caspase-3 and caspase-9 and inhibit GLI and Bcl-2. The 
enhancement in sensitivity to chemotherapeutical drugs is 
correlated with the suppression of Bcl-2 by GANT61.
Collectively, the SHH signalling pathway can regulate 
the tumour cell cycle and apoptosis at different molecu-
lar levels. The zinc finger transcription factor GLI plays 
an important role in the SHH signalling pathway. Our 
researches show that GANT61 promotes cell apoptosis and 
significantly inhibits cell proliferation and metastatic abil-
ity. GANT61 also can combine with cisplatin by enhanc-
ing cisplatin-induced apoptosis. Our findings show that 
GANT61 may be the effective targeted chemotherapeutic 
medicine in MB patients. Thus, it may be an attractive ther-
apeutic strategy to block the expression of GLI in MB.
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Fig. 6  GANT61 enhances the antiproliferative effects of cisplatin. 
We further determined whether combining GANT61 with cisplatin 
would enhance the effect. a Combined treatment reduced the IC50 
value of cisplatin from 34.47 to 30.02 µmol/L. b The down-regulation 
in Bcl-2 expression was significantly greater in the groups treated 
with both GANT61 (10 µm/L) and cisplatin (30 µm/L) than those in 
the single treatment group. However, combination treatment emerged 
greater increase in Bax, caspase-3 and caspase-9 protein expression 
than either drug alone group
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